Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and...
-
SANTA MONICA, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Researchers from the Pacific Brain Health Center at Providence Saint John’s Health Center shared new findings showing that a structured...
-
SAN FRANCISCO, April 13, 2026 (GLOBE NEWSWIRE) -- Some 45 years ago, the first cases of AIDS appeared in New York, and then, everywhere. Three years later, Human Immunodeficiency Virus (HIV) was...
-
- Firefly’s total brain scan volumes have increased sequentially by higher percentages in each of the past four quarters - - Firefly is harnessing increased data and NVIDIA L40S GPU acceleration to...
-
Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer’s disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28%...
-
MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...
-
SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) phase of the XanaMIA trial...
-
MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...
-
Blinded safety data from the ongoing Phase 2 trial suggest no treatment-related amyloid-related imaging abnormalities (ARIA) with PRI-002 Drug Safety and Monitoring Board recommended continued...
-
MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...